PERFORM vs TACITO, the Segatella copri Problem, and the Commercial Frontier — Three Crossroads Facing FMT’s Clinical Translation | Making Cancer Immunotherapy Work with FMT, Vol. 3 (Final)
Series finale. Same metastatic RCC, contrasting designs: PERFORM (healthy donor, ipi/nivo) vs TACITO (ICI complete-responder donor, pembro+axitinib). The cross-trial Segatella copri context-dependent toxicity discovery (drives toxicity ONLY under dual ICI), the three-layer commercial map (Seres/Vedanta/Exeliom; Locus/Eligo; rational consortia), and structural implications for the global ecosystem. The clinical-translation year of FMT/LBP, synthesized.
